Renofab Construct SRL
The score of Renofab Construct shows with a free account.
See the score- Summary? / 5
- Balance sheet strength
- Liquidity
- Repayment capacity
- Profitability
- Trajectory
- Compliance and register
- Position in its sectorvs peers
- Supplier creditat 30 d
- Borrowing capacityborrowable
- Valuationcentral
Visible once signed in: create your account, the 14-day Pro trial is free.
Key figures 2025
Accounts of the company itself (not consolidated).
Renofab Construct's annual accounts
| 2025 | |
|---|---|
| Net result | 19,901 € |
| Equity | 19,901 € |
| Cash | 4,790 € |
| EBITDA | 25,672 € |
| Total assets | 43,669 € |
Filed annual accounts
- Year ended 31 Dec 2025filed on 27 Jul 2026
Renofab Construct's financial analysis
- Solvency45.6%sector median: 41.8%
- Current ratio
- Net margin
- ROE
- Financial debt / EBITDA
- Interest coverage
- Days sales outstanding (DSO)
Management and control of Renofab Construct
Renofab Construct's publications in the Belgian Gazette
Company number, VAT number and registered office
- Company number (CBE)
- 1013.542.508
- VAT number
- BE1013542508
- Peppol
- Registered · 0208:1013542508 · as of 30 Oct 2026
- Legal form
- SRL
- Incorporated
- 13 Sep 2024
- Registered office
- 1620 Drogenbos
- Latest accounts
- 2025 · filed on 27 Jul 2026
- Activity
- General construction of residential buildings (NACE 41001)
Renofab Construct (SRL) has been based in Drogenbos since 2024, active in: general construction of residential buildings. For 2025, it reports a net profit of 19,901 € and equity of 19,901 €; its revenue is not published. Its solvency stands at 45.6%, above the median of its sector (41.8%).
Companies similar to Renofab Construct
Companies in the same business, of comparable size and area, outside its group.
- S.M.W.I. Construction of residential and non-residential buildings Koekelberg · balance sheet 807,716 €
- DAN Fourniture Construction of residential and non-residential buildings Wemmel · balance sheet 31,351 €
- ACMS Construction of residential and non-residential buildings Koekelberg · balance sheet 39,368 €
- B&L Deco Construction of residential and non-residential buildings Sint-Genesius-Rode · balance sheet 53,904 €
- MLE Invest Construction of residential and non-residential buildings Landen · balance sheet 21,934 €
- Algemene bouwwerken Venneman Construction of residential and non-residential buildings Kortenberg · balance sheet 29 €
- Belga Renova Construction of residential and non-residential buildings Charleroi · balance sheet 16,332 €
- EGS Construction Construction of residential and non-residential buildings Overijse · balance sheet 24,673 €
Frequently asked questions about Renofab Construct
What is the revenue of Renofab Construct?
Renofab Construct files its accounts in a format where revenue is optional: it is not published for 2025.
What is the VAT number of Renofab Construct?
In Belgium, the VAT number is the company number prefixed with BE: BE1013542508 for Renofab Construct, if the company is VAT-registered. Its company number (CBE) is 1013.542.508.
Where is the registered office of Renofab Construct?
According to the CBE register, the registered office of Renofab Construct is in 1620 Drogenbos.
What is the equity of Renofab Construct?
At the close of the 2025 financial year, the equity of Renofab Construct amounts to 19,901 €, a solvency of 45.6% of total assets.
Who manages Renofab Construct?
The register lists 1 active mandates at Renofab Construct. Names and roles are in the full file, with the deeds published in the Belgian Gazette.
The full file of Renofab Construct
Directors and mandates, ownership network, Gazette deeds, ten years of accounts and ratios, Excel export, and Idonis's analysis in one question.
Open the full file →